We believe that through collaboration, we can advance drug discovery and development to make a real difference in the lives of patients. With our own investments into proprietary technology platforms forming the basis for highly cost effective R&D in a joint ecosystem, we focus on data-driven precision medicine and early disease relevance to drive up probabilities of success (PoS). Within our pipeline co-creation model, our partners benefit from flexible access to our state-of-the art technology platforms and experienced researchers and scientists to generate R&D returns and therapeutics from their variable costs forming a shared R&D economy.